Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Chemotherapy, Adjuvant"" wg kryterium: Temat


Tytuł:
Translation of IDEA trial results into clinical practice: Analysis of the implementation of a new guideline for colon cancer.
Autorzy:
van Rooijen KL; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Internal Medicine, Hospital St. Jansdal, Harderwijk, The Netherlands.
Derksen JWG; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Verkooijen HM; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Vink GR; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Koopman M; Department of Medical Oncology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Pokaż więcej
Źródło:
International journal of cancer [Int J Cancer] 2022 Oct 15; Vol. 151 (8), pp. 1270-1279. Date of Electronic Publication: 2022 Jun 21.
Typ publikacji:
Journal Article
MeSH Terms:
Chemotherapy, Adjuvant*/adverse effects
Colonic Neoplasms*/drug therapy
Colonic Neoplasms*/pathology
Oxaliplatin*/toxicity
Aged ; Clinical Trials as Topic ; Humans ; Neoplasm Staging ; Practice Guidelines as Topic
Czasopismo naukowe
Tytuł:
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel.
Autorzy:
Arboleda B; Puerto Rican Society of Mastology, HIMA San Pablo Oncology Hospital, Caguas, Puerto Rico.
Bartsch R; Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.
de Azambuja E; Institut Jules Bordet - Université Libre de Bruxelles, Brussels, Belgium.
Hamilton E; Breast and Gynecologic Research Program, Sarah Cannon Research Institute, Tennessee Oncology PLLC, Nashville, TN, USA.
Harbeck N; LMU Munich, University Hospital, Department of Obstetrics and Gynecology, Breast Center and Comprehensive Cancer Center (CCLMU), Munich, Germany.
Klemp J; University of Kansas Cancer Center, Kansas City, KS, USA.
Knauer M; Department of Pathology and Laboratory Medicine, Western University and London Health Sciences Centre, London, ON, Canada.
Kuemmel S; Department of Gynecology with Breast Center, Charité-Universitätsmedizin Berlin, Germany.
Mahtani R; Baptist Health South Florida, Miami, FL, USA.
Schwartzberg L; West Cancer Center, Memphis, TN, USA.
Villarreal-Garza C; Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Mexico.
Wolff A; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2022 Sep 02; Vol. 27 (9), pp. 722-731.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Chemotherapy, Adjuvant*/adverse effects
Female ; Humans ; Premenopause ; Prospective Studies ; Quality of Life
Czasopismo naukowe
Tytuł:
Utilization and outcomes of adjuvant therapy for stage II and III uterine leiomyosarcoma.
Autorzy:
Diggs A; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America; New York Presbyterian Hospital, United States of America.
Sia TY; Memorial Sloan Kettering Cancer Center, New York, NY, United States of America.
Huang Y; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America.
Gockley A; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America; Herbert Irving Comprehensive Cancer Center, United States of America; New York Presbyterian Hospital, United States of America.
Melamed A; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America; Herbert Irving Comprehensive Cancer Center, United States of America; New York Presbyterian Hospital, United States of America.
Khoury-Collado F; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America; Herbert Irving Comprehensive Cancer Center, United States of America; New York Presbyterian Hospital, United States of America.
St Clair C; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America; Herbert Irving Comprehensive Cancer Center, United States of America; New York Presbyterian Hospital, United States of America.
Hou JY; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America; Herbert Irving Comprehensive Cancer Center, United States of America; New York Presbyterian Hospital, United States of America.
Hershman DL; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America; Herbert Irving Comprehensive Cancer Center, United States of America; New York Presbyterian Hospital, United States of America.
Wright JD; Columbia University Vagelos College of Physicians and Surgeons, New York, NY, United States of America; Herbert Irving Comprehensive Cancer Center, United States of America; New York Presbyterian Hospital, United States of America. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2022 Aug; Vol. 166 (2), pp. 308-316. Date of Electronic Publication: 2022 Jun 02.
Typ publikacji:
Journal Article
MeSH Terms:
Chemotherapy, Adjuvant*/methods
Leiomyosarcoma*/pathology
Leiomyosarcoma*/therapy
Pelvic Neoplasms*/pathology
Pelvic Neoplasms*/therapy
Uterine Neoplasms*/pathology
Uterine Neoplasms*/therapy
Combined Modality Therapy ; Female ; Humans ; Neoplasm Staging ; Radiotherapy, Adjuvant/methods ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Retrospective analysis of adjuvant treatment for localized, operable uterine leiomyosarcoma.
Autorzy:
Chantharasamee J; Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.; Division of Medical Oncology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Wong K; Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
Potivongsajarn P; Department of Pathology, University of California, Los Angeles, California, USA.
Qorbani A; Department of Pathology, University of California, Los Angeles, California, USA.
Motamed N; Department of Pathology, University of California, Los Angeles, California, USA.
Brackert S; Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
Cohen J; Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California, Los Angeles, California, USA.
Chmielowski B; Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
Kalbasi A; Department of Radiation Oncology, University of California, Los Angeles, California, USA.
Rao J; Department of Pathology, University of California, Los Angeles, California, USA.
Nelson S; Department of Pathology, University of California, Los Angeles, California, USA.
Singh A; Division of Hematology-Oncology, Department of Medicine, University of California, Los Angeles, California, USA.
Pokaż więcej
Źródło:
Cancer medicine [Cancer Med] 2022 Aug; Vol. 11 (15), pp. 2906-2912. Date of Electronic Publication: 2022 Mar 20.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Chemotherapy, Adjuvant*/methods
Leiomyosarcoma*/drug therapy
Leiomyosarcoma*/surgery
Uterine Neoplasms*/drug therapy
Uterine Neoplasms*/surgery
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Female ; Humans ; Middle Aged ; Pelvic Neoplasms ; Prognosis ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer.
Autorzy:
Fadelu TA; Dana-Farber Cancer Institute, 450 Brookline Avenue, MA- 1B-17, Boston, MA, 02215, USA. temidayo_.; Harvard Medical School, Boston, MA, USA. temidayo_.
Erfani P; Harvard Medical School, Boston, MA, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Lormil J; Hôpital Universitaire de Mirebalais, Mirebalais, Haiti.; Zanmi Lasante, 8A, Santo 22H,, Croix-des-Bouquet, Haiti.
Damuse R; Hôpital Universitaire de Mirebalais, Mirebalais, Haiti.; Zanmi Lasante, 8A, Santo 22H,, Croix-des-Bouquet, Haiti.
Pierre V; Hôpital Universitaire de Mirebalais, Mirebalais, Haiti.; Zanmi Lasante, 8A, Santo 22H,, Croix-des-Bouquet, Haiti.
Slater S; Dana-Farber Cancer Institute, 450 Brookline Avenue, MA- 1B-17, Boston, MA, 02215, USA.; Harvard Medical School, Boston, MA, USA.
Triedman SA; Dana-Farber Cancer Institute, 450 Brookline Avenue, MA- 1B-17, Boston, MA, 02215, USA.; The Warren Alpert Medical School of Brown University, Providence, RI, USA.
Shulman LN; Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Rebbeck TR; Dana-Farber Cancer Institute, 450 Brookline Avenue, MA- 1B-17, Boston, MA, 02215, USA.; Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Pokaż więcej
Źródło:
Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Jun; Vol. 193 (3), pp. 625-635. Date of Electronic Publication: 2022 Apr 14.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/drug therapy
Breast Neoplasms*/epidemiology
Breast Neoplasms*/surgery
Chemotherapy, Adjuvant*
Female ; Haiti/epidemiology ; Humans ; Mastectomy ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA).
Autorzy:
Wang C; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Zhou Y; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Lin Y; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Mao F; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Guan J; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Zhang X; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Shen S; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Wang X; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Zhang Y; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Pan B; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Zhong Y; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Peng L; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Cao X; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Yao R; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Zhou X; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Xu C; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Xu Y; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China.
Sun Q; Department of Breast Surgery, Peking Union Medical College Hospital, No.41 DaMuCang Lane, Xicheng District, Beijing, 100032, China. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2022 Mar 14; Vol. 22 (1), pp. 269. Date of Electronic Publication: 2022 Mar 14.
Typ publikacji:
Clinical Trial Protocol; Journal Article; Multicenter Study
MeSH Terms:
Acrylamides/*administration & dosage
Albumins/*administration & dosage
Aminoquinolines/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Breast Neoplasms/*drug therapy
Chemotherapy, Adjuvant/*methods
Paclitaxel/*administration & dosage
Acrylamides/adverse effects ; Albumins/adverse effects ; Aminoquinolines/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Breast Neoplasms/metabolism ; Chemotherapy, Adjuvant/adverse effects ; Clinical Trials, Phase II as Topic ; Diarrhea/chemically induced ; Diarrhea/epidemiology ; Female ; Humans ; Incidence ; Neoplasm Staging ; Paclitaxel/adverse effects ; Prospective Studies ; Quality of Life ; Receptor, ErbB-2/metabolism ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Combinatory statuses of tumor stromal percentage and tumor infiltrating lymphocytes as prognostic factors in stage III colorectal cancers.
Autorzy:
Jin HY; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.; Laboratory of Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Yoo SY; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
Lee JA; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
Wen X; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.; Laboratory of Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Kim Y; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.; Laboratory of Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Park HE; Department of Pathology, Seoul National University Boramae Hospital, Seoul, South Korea.
Kwak Y; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
Cho NY; Laboratory of Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Bae JM; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.; Laboratory of Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Kim JH; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
Lee HS; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.
Kang GH; Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea.; Laboratory of Epigenetics, Cancer Research Institute, Seoul National University College of Medicine, Seoul, South Korea.
Pokaż więcej
Źródło:
Journal of gastroenterology and hepatology [J Gastroenterol Hepatol] 2022 Mar; Vol. 37 (3), pp. 551-557. Date of Electronic Publication: 2022 Jan 25.
Typ publikacji:
Journal Article
MeSH Terms:
Chemotherapy, Adjuvant*
Colorectal Neoplasms*/drug therapy
Colorectal Neoplasms*/pathology
Lymphocytes, Tumor-Infiltrating*/pathology
Humans ; Neoplasm Staging ; Prognosis ; Tumor Microenvironment
Czasopismo naukowe
Tytuł:
CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
Autorzy:
Alarid-Escudero F; Division of Public Administration, Center for Research and Teaching in Economics, Aguascalientes, Aguascalientes, Mexico. Electronic address: .
Schrag D; Division of Population Sciences, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Kuntz KM; Division of Health Policy and Management, University of Minnesota School of Public Health, Minneapolis, MN, USA.
Pokaż więcej
Źródło:
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2022 Mar; Vol. 25 (3), pp. 409-418. Date of Electronic Publication: 2021 Nov 02.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*economics
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
CDX2 Transcription Factor/*biosynthesis
Chemotherapy, Adjuvant/*economics
Colonic Neoplasms/*drug therapy
Colonic Neoplasms/*pathology
Aged ; Biomarkers, Tumor ; Chemotherapy, Adjuvant/methods ; Colonic Neoplasms/mortality ; Colonic Neoplasms/therapy ; Cost-Benefit Analysis ; Decision Support Techniques ; Disease-Free Survival ; Female ; Fluorouracil/economics ; Fluorouracil/therapeutic use ; Humans ; Leucovorin/economics ; Leucovorin/therapeutic use ; Male ; Markov Chains ; Middle Aged ; Models, Economic ; Neoplasm Staging ; Organoplatinum Compounds/economics ; Organoplatinum Compounds/therapeutic use ; Quality-Adjusted Life Years ; Risk Assessment
SCR Protocol:
Folfox protocol
Czasopismo naukowe
Tytuł:
Time to halt perioperative chemotherapy for resectable colorectal liver metastasis?
Autorzy:
Søreide K; Department of Gastrointestinal Surgery, Hepatopancreatobiliary Unit, Stavanger University Hospital and University of Bergen, Norway.
Pokaż więcej
Źródło:
The British journal of surgery [Br J Surg] 2022 Feb 24; Vol. 109 (3), pp. 242-243.
Typ publikacji:
Journal Article
MeSH Terms:
Chemotherapy, Adjuvant*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Colorectal Neoplasms/*pathology
Liver Neoplasms/*drug therapy
Liver Neoplasms/*secondary
Colorectal Neoplasms/drug therapy ; Hepatectomy ; Humans ; Liver Neoplasms/surgery
Czasopismo naukowe
Tytuł:
Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery.
Autorzy:
Rahman S; School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.; Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
Thomas B; Department of Oncology, Velindre University NHS Trust, Cardiff, UK.
Maynard N; Department of Upper Gastrointestinal Surgery, Oxford University Hospitals NHS Trust, Oxford, UK.
Park MH; Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
Wahedally M; Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
Trudgill N; Department of Gastroenterology, Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.
Crosby T; Department of Oncology, Velindre University NHS Trust, Cardiff, UK.
Cromwell DA; Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK.
Underwood TJ; School of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK.
Pokaż więcej
Źródło:
The British journal of surgery [Br J Surg] 2022 Feb 01; Vol. 109 (2), pp. 227-236.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Chemotherapy, Adjuvant*
Esophagogastric Junction*/surgery
Adenocarcinoma/*drug therapy
Esophageal Neoplasms/*drug therapy
Postoperative Care/*methods
Preoperative Care/*methods
Stomach Neoplasms/*drug therapy
Adenocarcinoma/surgery ; Aged ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemoradiotherapy, Adjuvant ; Esophageal Neoplasms/surgery ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Stomach Neoplasms/surgery ; Survival Analysis
Czasopismo naukowe
Tytuł:
Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.
Autorzy:
Matulonis UA; Dana-Farber Cancer Institute, Boston, MA, USA. Electronic address: Ursula_.
Huang HQ; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: .
Filiaci VL; NRG Oncology, Clinical Trial Development Division, Biostatistics & Bioinformatics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA. Electronic address: .
Randall M; University of Kentucky, Department of Radiation Medicine, Lexington, KY, USA. Electronic address: .
DiSilvestro PA; Women and Infants Hospital in Rhode Island/The Warren Alpert Medical School of Brown University, Providence, RI, USA. Electronic address: .
Moxley KM; Stephenson Cancer Center Gynecologic Cancers Clinic, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: .
Fowler JM; Ohio State University Comprehensive Cancer Center, Obstetrics and Gynecology, Hilliard, OH, USA. Electronic address: .
Powell MA; Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, USA. Electronic address: .
Spirtos NM; Women's Cancer Center of Nevada, Las Vegas, NV, USA. Electronic address: .
Tewari KS; University of California Irvine Medical Center, Irvine, CA, USA. Electronic address: .
Richards WE; Georgia Core, Gynecologic Oncology, St. Joseph's Candler Oncology, Savannah, GA, USA.
Nakayama JM; UH Cleveland Medical Center. University Hospitals, Cleveland, OH, USA. Electronic address: .
Mutch DG; Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO, USA. Electronic address: .
Miller DS; University of Texas Southwestern Medical Center, Dallas, TX, USA. Electronic address: .
Matei D; Northwestern University, Division of Gynecologic Oncology Chicago, IL, USA. Electronic address: .
Wenzel LB; University of California Irvine Medical Center, Irvine, CA, USA. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2022 Feb; Vol. 164 (2), pp. 428-436. Date of Electronic Publication: 2021 Dec 11.
Typ publikacji:
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms:
Chemoradiotherapy, Adjuvant*
Chemotherapy, Adjuvant*
Quality of Life*
Endometrial Neoplasms/*therapy
Gastrointestinal Diseases/*physiopathology
Peripheral Nervous System Diseases/*physiopathology
Carboplatin/administration & dosage ; Cisplatin/administration & dosage ; Disease-Free Survival ; Endometrial Neoplasms/pathology ; Female ; Functional Status ; Gastrointestinal Diseases/epidemiology ; Humans ; Neoplasm Staging ; Paclitaxel/administration & dosage ; Patient Reported Outcome Measures ; Peripheral Nervous System Diseases/chemically induced ; Peripheral Nervous System Diseases/epidemiology
Czasopismo naukowe
Tytuł:
A Propensity Score Analysis of Chemotherapy Use in Patients With Resectable Gallbladder Cancer.
Autorzy:
Ozer M; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas.; Department of Internal Medicine, Capital Health Regional Medical Center, Trenton, New Jersey.
Goksu SY; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas.
Sanford NN; Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas.
Porembka M; Division of Surgical Oncology, Department of Surgery, University of Texas Southwestern Medical Center, Dallas.
Khurshid H; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas.
Ahn C; Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas.
Maxwell MC; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas.
Beg MS; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas.
Kazmi SM; Division of Hematology and Oncology, University of Texas Southwestern Medical Center, Dallas.
Pokaż więcej
Źródło:
JAMA network open [JAMA Netw Open] 2022 Feb 01; Vol. 5 (2), pp. e2146912. Date of Electronic Publication: 2022 Feb 01.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Chemotherapy, Adjuvant*
Neoadjuvant Therapy*
Gallbladder Neoplasms/*drug therapy
Aged ; Female ; Gallbladder Neoplasms/mortality ; Gallbladder Neoplasms/pathology ; Gallbladder Neoplasms/surgery ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Propensity Score ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł:
Union is strength: Textbook outcome with perioperative chemotherapy compliance decreases the risk of death in advanced gastric cancer patients.
Autorzy:
Sędłak K; Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080, Lublin, Poland.
Rawicz-Pruszyński K; Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080, Lublin, Poland. Electronic address: .
Mlak R; Department of Human Physiology, Medical University of Lublin, Radziwiłłowska 11 St., 20-080, Lublin, Poland.
Gęca K; Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080, Lublin, Poland.
Skórzewska M; Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080, Lublin, Poland.
Pelc Z; Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080, Lublin, Poland.
Małecka-Massalska T; Department of Human Physiology, Medical University of Lublin, Radziwiłłowska 11 St., 20-080, Lublin, Poland.
Polkowski WP; Department of Surgical Oncology, Medical University of Lublin, Radziwiłłowska 13 St., 20-080, Lublin, Poland.
Pokaż więcej
Źródło:
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2022 Feb; Vol. 48 (2), pp. 356-361. Date of Electronic Publication: 2021 Aug 11.
Typ publikacji:
Journal Article
MeSH Terms:
Chemotherapy, Adjuvant*
Gastrectomy*
Neoadjuvant Therapy*
Adenocarcinoma/*therapy
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Perioperative Care/*standards
Stomach Neoplasms/*therapy
Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Capecitabine/administration & dosage ; Docetaxel/administration & dosage ; Epirubicin/administration & dosage ; Female ; Fluorouracil/administration & dosage ; Guideline Adherence/statistics & numerical data ; Humans ; Leucovorin/administration & dosage ; Male ; Middle Aged ; Outcome and Process Assessment, Health Care ; Oxaliplatin/administration & dosage ; Postoperative Complications/epidemiology ; Practice Guidelines as Topic ; Stomach Neoplasms/pathology ; Survival Rate
Czasopismo naukowe
Tytuł:
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis.
Autorzy:
Tomasello G; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 19, 20122, Milan, Italy.
Ghidini M; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 19, 20122, Milan, Italy.
Galassi B; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 19, 20122, Milan, Italy.
Grossi F; Medical Oncology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via della Commenda 19, 20122, Milan, Italy.
Luciani A; Medical Oncology Unit, Medical Sciences Department, ASST Bergamo Ovest, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy.
Petrelli F; Medical Oncology Unit, Medical Sciences Department, ASST Bergamo Ovest, Piazzale Ospedale 1, 24047, Treviglio, BG, Italy. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2022 Jan 20; Vol. 12 (1), pp. 1055. Date of Electronic Publication: 2022 Jan 20.
Typ publikacji:
Journal Article; Meta-Analysis; Systematic Review
MeSH Terms:
Chemotherapy, Adjuvant*
DNA Mismatch Repair*
Microsatellite Instability*
Colonic Neoplasms/*drug therapy
Antineoplastic Agents/therapeutic use ; Disease-Free Survival ; Humans ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Racial disparities in non-recommendation of adjuvant chemotherapy in stage II-III ovarian cancer.
Autorzy:
Matthews BJ; Department of Gynecology & Obstetrics, Johns Hopkins Medicine, Baltimore, MD, USA.
Qureshi MM; Boston University School of Medicine, Boston, MA, USA; Department of Radiation Oncology, Boston Medical Center, Boston, MA, USA.
Fiascone SJ; Boston University School of Medicine, Boston, MA, USA; Department of Obstetrics & Gynecology, Boston Medical Center, Boston, MA, USA.
Nitschmann CC; Department of Gynecology, Beth Israel Lahey Health, Burlington, MA, USA.
Oladeru OT; Harvard Radiation Oncology Program, Boston, MA, USA.
Truong MT; Boston University School of Medicine, Boston, MA, USA; Department of Radiation Oncology, Boston Medical Center, Boston, MA, USA.
Hirsch AE; Boston University School of Medicine, Boston, MA, USA; Department of Radiation Oncology, Boston Medical Center, Boston, MA, USA.
Mak KS; Boston University School of Medicine, Boston, MA, USA; Department of Radiation Oncology, Boston Medical Center, Boston, MA, USA.
Dyer MA; Department of Radiation Oncology, Dana-Farber/Brigham and Women's Cancer Center, Harvard Medical School, Boston, MA, USA. Electronic address: .
Pokaż więcej
Źródło:
Gynecologic oncology [Gynecol Oncol] 2022 Jan; Vol. 164 (1), pp. 27-33. Date of Electronic Publication: 2021 Nov 14.
Typ publikacji:
Journal Article
MeSH Terms:
Chemotherapy, Adjuvant*
Healthcare Disparities*
Outcome Assessment, Health Care*
Antineoplastic Agents/*therapeutic use
Ovarian Neoplasms/*drug therapy
Adult ; Aged ; Antineoplastic Agents/administration & dosage ; Databases, Factual ; Ethnicity ; Female ; Humans ; Kaplan-Meier Estimate ; Middle Aged ; Neoplasm Staging ; Ovarian Neoplasms/ethnology ; Ovarian Neoplasms/mortality ; Ovarian Neoplasms/pathology ; United States
Czasopismo naukowe
Tytuł:
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon.
Autorzy:
Passiglia F; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy. Electronic address: .
Bertaglia V; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Reale ML; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy. Electronic address: .
Delcuratolo MD; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Tabbò F; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Olmetto E; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy.
Capelletto E; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy. Electronic address: .
Bironzo P; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy. Electronic address: .
Novello S; Department of Oncology, University of Turin, S. Luigi Gonzaga Hospital, Orbassano (TO), Italy. Electronic address: .
Pokaż więcej
Źródło:
Cancer treatment reviews [Cancer Treat Rev] 2021 Dec; Vol. 101, pp. 102308. Date of Electronic Publication: 2021 Oct 18.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Carcinoma, Non-Small-Cell Lung*/immunology
Carcinoma, Non-Small-Cell Lung*/pathology
Carcinoma, Non-Small-Cell Lung*/therapy
Chemotherapy, Adjuvant*/methods
Chemotherapy, Adjuvant*/trends
Lung Neoplasms*/immunology
Lung Neoplasms*/pathology
Lung Neoplasms*/therapy
Immune Checkpoint Inhibitors/*pharmacology
Antineoplastic Protocols/classification ; Clinical Trials as Topic ; Combined Modality Therapy/methods ; Humans ; Immunotherapy/methods ; Neoplasm Staging
Czasopismo naukowe
Tytuł:
Prognosis and effectiveness of chemotherapy for medullary breast carcinoma.
Autorzy:
Aihara T; Breast Center, Aihara Hospital, 3-4-30, Makiochi, Minoh, Osaka, 562-0004, Japan. .
Kumamaru H; Department of Healthcare Quality Assessment, University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Ishitobi M; Department of Breast Surgery, Mie University Hospital, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
Miyashita M; Department of Breast and Endocrine Surgical Oncology, Tohoku University School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan.
Miyata H; Department of Healthcare Quality Assessment, University of Tokyo, 7-3-1 Hongo, Bunkyo-Ku, Tokyo, 113-8655, Japan.
Tamura K; Department of Medical Oncology, Shimane University Hospital, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Yoshida M; Department of Diagnostic Pathology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo-Ku, Tokyo, 104-0045, Japan.
Ogo E; Department of Radiology, Kurume University School of Medicine, 67 Asahisahi-Machi, Kurume, Fukuoka, 830-0011, Japan.
Nagahashi M; Department of Surgery, Division of Breast and Endocrine Surgery, School of Medicine, Hyogo Medical University, 1-1 Mukogawa-Cho, Nishinomiya, Hyogo, 663-8501, Japan.
Asaga S; Department of Breast Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
Kojima Y; Division of Breast and Endocrine Surgery, Department of Surgery, St. Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-Ku, Kawasaki, Kanagawa, 216-8511, Japan.
Kadoya T; Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, Hiroshima, 734-8551, Japan.
Aogi K; Department of Breast Oncology, National Hospital Organization Shikoku Cancer Center, 160 Ko, Minamiumemoto-Machi, Matsuyama, Ehime, 791-0280, Japan.
Niikura N; Department of Breast Oncology, Tokai University School of Medicine, 143 Shimokasuya, Isehara, Kanagawa, 259-1193, Japan.
Iijima K; Department of Breast Oncology, Juntendo University, 2-1-1 Hongo, Bunkyo-Ku, Tokyo, 113-8421, Japan.
Hayashi N; Department of Breast Surgical Oncology, St. Luke's International Hospital, 9-1 Akashi-Cho, Chuo-Ku, Tokyo, 104-8560, Japan.
Kubo M; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, 3-1-1, Maidashi, Higashi-Ku, Fukuoka City, Fukuoka, 812-8582, Japan.
Yamamoto Y; Department of Breast and Endocrine Surgery, Kumamoto University Hospital, 1-1-1 Honjo, Chuo-Ku, Kumamoto-Shi, Kumamoto, 860-8556, Japan.
Takeuchi Y; Division of Medical Statistics, Department of Social Medicine, Faculty of Medicine, Toho University, 5-21-16 Omorinishi, Ota-Ku, Tokyo, 143-8540, Japan.
Imoto S; Department of Breast Surgery, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo, 181-8611, Japan.
Jinno H; Department of Surgery, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-Ku, Tokyo, 173-8606, Japan.
Pokaż więcej
Źródło:
Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Dec; Vol. 196 (3), pp. 635-645. Date of Electronic Publication: 2022 Oct 23.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/pathology
Carcinoma, Ductal, Breast*/drug therapy
Carcinoma, Ductal, Breast*/pathology
Humans ; Female ; Receptor, ErbB-2 ; Prognosis ; Chemotherapy, Adjuvant
Czasopismo naukowe
Tytuł:
Does neoadjuvant chemotherapy provide a survival benefit in maxillofacial osteosarcoma: A systematic review and pooled analysis.
Autorzy:
Khadembaschi D; School of Medicine, University of Queensland, Herston, Australia. Electronic address: .
Jafri M; Department of Oncology, University Hospital Birmingham, United Kingdom.
Praveen P; Department of Maxillofacial Surgery, University Hospital Birmingham, United Kingdom.
Parmar S; Department of Maxillofacial Surgery, University Hospital Birmingham, United Kingdom.
Breik O; Department of Maxillofacial Surgery, Royal Brisbane and Women's Hospital, Queensland, Australia.
Pokaż więcej
Źródło:
Oral oncology [Oral Oncol] 2022 Dec; Vol. 135, pp. 106133. Date of Electronic Publication: 2022 Oct 10.
Typ publikacji:
Systematic Review; Journal Article; Review
MeSH Terms:
Osteosarcoma*/pathology
Head and Neck Neoplasms*/drug therapy
Bone Neoplasms*/pathology
Humans ; Neoadjuvant Therapy ; Chemotherapy, Adjuvant
Czasopismo naukowe
Tytuł:
Survival outcomes of patients with muscle-invasive bladder cancer according to pathological response at radical cystectomy with or without neo-adjuvant chemotherapy: a case-control matching study.
Autorzy:
van Ginkel N; Department of Urology, Amsterdam University Medical Center, Location VUmc, De Boelelaan 1117, Postbus 7057, 1007 MB, Amsterdam, The Netherlands.
Hermans TJN; Department of Urology, Maastricht University Medical Centre, Maastricht, The Netherlands.
Meijer D; Department of Urology, Amsterdam University Medical Center, Location VUmc, De Boelelaan 1117, Postbus 7057, 1007 MB, Amsterdam, The Netherlands.
Boormans JL; Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Voortman J; Department of Medical Oncology, Amsterdam UMC, Location VUmc, Amsterdam, The Netherlands.
Mertens L; Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Beek SC; Department of Urology, Erasmus University Medical Centre, Rotterdam, The Netherlands.
Vis AN; Department of Urology, Amsterdam University Medical Center, Location VUmc, De Boelelaan 1117, Postbus 7057, 1007 MB, Amsterdam, The Netherlands. .
Pokaż więcej
Corporate Authors:
Dutch Cystectomy Snapshot Research Group
Źródło:
International urology and nephrology [Int Urol Nephrol] 2022 Dec; Vol. 54 (12), pp. 3145-3152. Date of Electronic Publication: 2022 Aug 23.
Typ publikacji:
Journal Article
MeSH Terms:
Cystectomy*
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/surgery
Humans ; Neoadjuvant Therapy ; Chemotherapy, Adjuvant ; Case-Control Studies ; Muscles/pathology ; Neoplasm Invasiveness/pathology ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Primary Alveolar Soft Part Sarcoma of Bone: A Rare Occurrence in 8 Patients, Posing a Diagnostic Challenge.
Autorzy:
Kaur R; From the Department of Pathology (Kaur, Ramadwar, Rekhi, Panjwani), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Ramadwar M; From the Department of Pathology (Kaur, Ramadwar, Rekhi, Panjwani), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Gulia A; Department of Orthopaedic Oncology (Gulia, Pruthi, Puri, Nayak), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Pruthi M; Department of Orthopaedic Oncology (Gulia, Pruthi, Puri, Nayak), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Rekhi B; From the Department of Pathology (Kaur, Ramadwar, Rekhi, Panjwani), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Panjwani PK; From the Department of Pathology (Kaur, Ramadwar, Rekhi, Panjwani), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Puri A; Department of Orthopaedic Oncology (Gulia, Pruthi, Puri, Nayak), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Nayak P; Department of Orthopaedic Oncology (Gulia, Pruthi, Puri, Nayak), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Bajpai J; Department of Medical Oncology (Bajpai), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Janu A; Department of Radiodiagnosis (Janu), Tata Memorial Hospital, Parel, Mumbai, Maharashtra, India.
Pokaż więcej
Źródło:
Archives of pathology & laboratory medicine [Arch Pathol Lab Med] 2022 Dec 01; Vol. 146 (12), pp. 1514-1522.
Typ publikacji:
Journal Article
MeSH Terms:
Sarcoma, Alveolar Soft Part*/diagnosis
Sarcoma, Alveolar Soft Part*/pathology
Sarcoma, Alveolar Soft Part*/secondary
Soft Tissue Neoplasms*/pathology
Humans ; Male ; Female ; Adolescent ; Young Adult ; Adult ; Middle Aged ; Immunohistochemistry ; Diagnosis, Differential ; Chemotherapy, Adjuvant
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz